Anti-Matriptase-2 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the cytoplasmic domain of human Matriptase-2 (TMPRSS6), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Monkey
UniProt
Q8IU80
Size
100ug
Cat. #
RP5Matriptase2

In stock

SKU
RP-Matriptase2

Options

As low as: $130.00

Target Overview

Matriptase-2 (transmembrane protease serine 6, TMPRSS6; EC 3.4.21.-) is an 811-residue type II transmembrane serine protease anchored in the cell membrane (UniProt Q8IU80). The enzyme plays a central role in systemic iron homeostasis by proteolytically cleaving cell-surface hemojuvelin (HJV), a co-receptor for bone morphogenetic proteins that positively regulates hepcidin expression. By suppressing HJV, Matriptase-2 inhibits hepcidin production in hepatocytes, thereby promoting iron absorption and mobilization from stores. Loss-of-function mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA), a disorder characterized by microcytic anemia unresponsive to oral iron supplementation. Conversely, therapeutic targeting of TMPRSS6 with monoclonal antibodies or antisense oligonucleotides is being pursued to elevate hepcidin levels in conditions of iron overload or ineffective erythropoiesis. Researchers study Matriptase-2 to understand the hepcidin-ferroportin regulatory axis, iron metabolism disorders, and potential interventions in hemochromatosis and beta-thalassemia.

Background

Matriptase-2 functions as a membrane-anchored serine protease that directly cleaves hemojuvelin, reducing its availability at the hepatocyte surface and thereby lowering SMAD-dependent transcription of hepcidin. This mechanism positions TMPRSS6 as a key suppressor of hepcidin synthesis under conditions of iron demand. Hemojuvelin cleavage by Matriptase-2 has been demonstrated in cell-based assays and mouse models, where TMPRSS6 deficiency leads to inappropriately high hepcidin levels, impaired duodenal iron absorption, and microcytic anemia resembling human IRIDA. Non-coding and missense variants in TMPRSS6 have been associated with variability in iron status among monoallelic carriers, suggesting dosage-sensitive regulation of the pathway. Recent work has identified TMPRSS6 as a therapeutic target for disorders characterized by hepcidin deficiency, such as hereditary hemochromatosis and transfusion-dependent anemias. A phase 1 trial of DISC-3405, a humanized monoclonal antibody targeting TMPRSS6, demonstrated dose-dependent increases in hepcidin in healthy volunteers, supporting the feasibility of antibody-mediated TMPRSS6 inhibition. Genome-wide association studies have linked TMPRSS6 polymorphisms to hepatic iron content and inflammation markers in large population cohorts, underscoring its broader relevance to liver pathophysiology. Antibody reagents targeting the cytoplasmic domain enable detection of full-length Matriptase-2 in lysates from hepatocytes, duodenal enterocytes, and erythroid precursors, facilitating analysis of protease expression and post-translational regulation in physiological and disease contexts.

References

  1. Liu G et al (2026) A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers. J Clin Pharmacol. PubMed · DOI: 10.1002/jcph.70199
  2. Hoving V et al (2026) TMPRSS6 Non-Coding Variants in the Expression of Iron Refractory Iron Deficiency Anemia in Monoallelic Subjects. Genes (Basel). PubMed · DOI: 10.3390/genes17010074
  3. Meena D et al (2026) Unravelling genetic susceptibility and causal factors in liver health using MRI quantification of inflammation, fat and iron in the liver. Hum Genomics. PubMed · DOI: 10.1186/s40246-026-00913-2
  4. Mansour GK et al (2025) Therapeutic targeting of the hepcidin-ferroportin axis and erythropoietic modulators: a narrative review. Front Med (Lausanne). PubMed · DOI: 10.3389/fmed.2025.1726337

Additional Specifications

Gene Symbol TMPRSS6
UniProt ID Q8IU80
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Monkey
Pack Size 100ug
Immunogen (Cytoplasmic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 1-55.
Immunogen (Â Stem Region)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 36-55.
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 761-811.
Immunogen (Cub Domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 213-336.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 577-811.
Alternate Names Transmembrane protease serine 6, TMPRSS6, Matriptase-2

Frequently Asked Questions

What molecular weight band should I expect for Matriptase-2 on Western blot?

Full-length Matriptase-2 (TMPRSS6) migrates at approximately 90-95 kDa on reducing SDS-PAGE, consistent with the 811-residue type II transmembrane protease structure. You may also detect proteolytic fragments around 60-70 kDa, representing the shed serine protease domain after autocatalytic cleavage. Band intensity and fragment pattern depend on cell type and activation state. Hepatocyte lysates typically show both forms. If you observe only lower molecular weight species, consider whether your sample contains active protease that has undergone maturation. Always include a positive control lysate from liver or hepatocyte lines known to express TMPRSS6.

Does this Matriptase-2 antibody cross-react with mouse or monkey samples?

This polyclonal antibody is validated for human Matriptase-2 and predicted to cross-react with mouse and monkey based on sequence homology in the immunogen region. Human and mouse TMPRSS6 share approximately 75 percent amino acid identity overall, with higher conservation in the catalytic domain. For mouse samples, start with the recommended 1:1000 dilution and optimize empirically. Monkey reactivity is predicted but not experimentally validated. If working with non-human samples, include a known positive control and be prepared to adjust dilution or blocking conditions. We recommend pilot experiments to confirm signal specificity before committing to large sample sets.

What is the recommended starting dilution for Western blot with this antibody?

Start at 1:1000 dilution in blocking buffer for Western blot of human samples. This polyclonal was raised in rabbit and typically provides robust signal at this concentration when detecting endogenous Matriptase-2 in hepatocyte or liver lysates. If working with overexpression systems or samples with high TMPRSS6 abundance, you may achieve adequate signal at 1:2000 or even 1:5000. Conversely, samples with low expression may require 1:500. Incubate overnight at 4°C or two hours at room temperature. Use standard HRP-conjugated anti-rabbit secondary at 1:5000 to 1:10000. Titrate against your specific lysate to balance signal and background.

Which tissues or cell lines serve as good positive controls for Matriptase-2?

Liver tissue and primary hepatocytes are the gold standard positive controls, as TMPRSS6 is predominantly expressed in the liver where it regulates hepcidin production. Human hepatocyte cell lines such as HepG2 or Huh7 also express detectable Matriptase-2, though levels may be lower than primary cells. Duodenal enterocytes show modest expression. Avoid using fibroblasts, lymphocytes, or most cancer cell lines unless they are known to aberrantly express TMPRSS6. For negative controls, consider tissues with negligible expression such as brain or skeletal muscle. If developing an iron metabolism model, compare wild-type versus TMPRSS6-knockdown cells to confirm antibody specificity.

Can this antibody detect the difference between active and inactive Matriptase-2?

This polyclonal recognizes epitopes in the full-length protein and likely binds both zymogen and cleaved forms, so it will not selectively detect only active Matriptase-2. The enzyme undergoes autocatalytic activation that releases the serine protease domain from the membrane-bound stem region. On Western blot you may observe multiple bands corresponding to precursor and processed forms, but distinguishing zymogen from active protease requires functional assays or antibodies specific to neo-epitopes generated during activation. If your research question centers on activation state, consider complementing immunoblotting with activity assays measuring hemojuvelin cleavage or hepcidin reporter readouts in cultured hepatocytes.

What sample preparation considerations are important for detecting Matriptase-2?

Because Matriptase-2 is a type II transmembrane protease, use lysis buffers containing non-ionic detergent such as 1 percent Triton X-100 or NP-40 to solubilize membrane proteins effectively. RIPA buffer works well. Include protease inhibitors to prevent autodegradation, particularly if studying the zymogen form. For tissue samples, snap-freeze in liquid nitrogen immediately after harvest to preserve protein integrity. Liver homogenates should be clarified by centrifugation at 10,000 to 15,000 g for ten minutes at 4°C. Load 20 to 50 micrograms total protein per lane for endogenous detection. Avoid repeated freeze-thaw cycles, which can promote aggregation or cleavage.

How should I store this Matriptase-2 antibody and what is the expected shelf life?

Store the antibody at minus 20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titre and increase aggregation. Glycerol or BSA in the formulation typically stabilizes polyclonals during storage. Once thawed, an aliquot remains stable at 4°C for up to one month; for longer bench use, add 0.02 to 0.05 percent sodium azide as preservative. Do not store diluted antibody for more than a few days. Under these conditions, rabbit polyclonals generally retain activity for two to three years from manufacture date. If you observe loss of signal or increased background over time, prepare a fresh aliquot and re-optimize dilution.

Does Matriptase-2 expression vary with iron status in hepatocyte cultures?

TMPRSS6 expression itself is relatively stable, but the functional significance of Matriptase-2 becomes more apparent under iron-deficient conditions when the hepcidin-suppressive pathway is engaged. In cultured hepatocytes, iron depletion or treatment with iron chelators does not dramatically upregulate TMPRSS6 mRNA or protein in most studies, unlike the robust induction seen with transferrin receptor 1. Instead, the protease activity toward hemojuvelin becomes physiologically critical. If modeling iron homeostasis, compare hepcidin output and hemojuvelin cleavage rather than total Matriptase-2 protein. For Western blot experiments, baseline expression in standard culture medium should be readily detectable without iron manipulation.

Western blot validation for RP-Matriptase2 — 3 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Matriptase-2: Carboxyterminal end — WB validation
WB · Panel 1 Matriptase-2: Carboxyterminal end
Matriptase-2: Cub Domain — WB validation
WB · Panel 2 Matriptase-2: Cub Domain
Matriptase-2: Catalytic domain — WB validation
WB · Panel 3 Matriptase-2: Catalytic domain

Custom validation studies available on request — contact us.

Also known as:

  • Transmembrane protease serine 6
  • TMPRSS6
  • Matriptase-2
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →